TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06528067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation
Description: 10 minute per day, 8 week digital meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute per day, 8 week digital meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Motivation
Description: A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
Study: NCT05083091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and Attention Training
Description: Guided mindfulness meditation with attention monitoring and acceptance skills training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness training
Description: Guided mindfulness meditation, no attention monitoring or acceptance skills training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Condition
Description: Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
Study: NCT06173765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: freeze-dried whole strawberry powder 36 g powder
Description: After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: freeze-dried whole strawberry powder 12 g
Description: After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: freeze-dried control powder 0 g strawberry
Description: After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm.
Study: NCT06043518

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Use of functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Use of functional and structural MRI in both the brain and the spinal cord and questionnaires.
Study: NCT06220838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-101
Description: All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
Study: NCT06102499

Intervention type: DEVICE
Intervention: SpO2 and SaO2 comparison
Description: Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded

Intervention type: DEVICE
Intervention: SpO2 and SaO2 comparison
Description: Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
Study: NCT06574217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones (StSt)
Description: StSt is an individual-level intervention designed to help youth make healthy decisions. StSt is delivered in-person by an adult guide during four \~30-50 minute sessions over a period of up to 8 weeks. The adult guide leads the youth through health-focused discussions related to identifying personal values, making a social network map, and then creating and refining individualized plans.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Like
Description: Like is an hour-long film that discusses the impact of social media on the brain. Study staff will organize for each individual participant to watch the film in-person. The film does not include information related to the outcomes of interest for the study.
Study: NCT04794582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProGrip™ Self-Gripping Polyester Mesh
Description: Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
Study: NCT06214793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taletrectinib
Description: Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
Study: NCT04816877

Intervention type: DRUG
Intervention: Opioid
Description: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.

Intervention type: DRUG
Intervention: Opioid
Description: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
Study: NCT06074159

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-clinic report-back
Description: Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-clinic report-back
Description: Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
Study: NCT06381375

Intervention type: OTHER
Intervention: Anti Tuberculosis Drug
Description: 1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events).
Study: NCT04872465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS
Description: We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham
Description: Participants will receive sham (placebo) TBS treatment the same as experimental group
Study: NCT06050421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO-DBT)
Description: RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
Study: NCT04787666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet
Description: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet
Description: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet
Description: Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
Study: NCT06652113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine and levothyroxine
Description: Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.

Intervention type: DRUG
Group type: OTHER
Intervention: Levothyroxine
Description: Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
Study: NCT04754425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and bone marrow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study: NCT06428747

Intervention type: DIAGNOSTIC_TEST
Intervention: b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).
Description: detection of micro-particles

Intervention type: DIAGNOSTIC_TEST
Intervention: b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).
Description: detection of micro-particles
Study: NCT04800978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAVC-C+Durvalumab
Description: * Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion
Study: NCT06606106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537031
Description: Administered SC
Study: NCT06155981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coke Zero
Description: Coca-Cola Zero Sugar drink will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coke
Description: Coca-Cola drink will be given.
Study: NCT05449639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relief implantation
Description: The device will be implanted by endoscopic procedure by a standard resectoscope.
Study: NCT05103761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study diet
Description: A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low glycemic index treatment diet
Description: A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
Study: NCT05812573

Intervention type: OTHER
Intervention: no intervention
Description: No intervention, only observation
Study: NCT06086912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031
Description: Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031
Description: Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031
Description: Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
Study: NCT04296565

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WATER+CT
Description: This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
Study: NCT05846581

Intervention type: DEVICE
Intervention: GORE® ACUSEAL Vascular Graft
Description: The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected.
Study: NCT06606106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537031
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537031
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06636630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadruple scleral flap
Description: Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double scleral flap
Description: The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
Study: NCT05578404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to Vit D
Study: NCT04849234

Intervention type: BEHAVIORAL
Intervention: newborn cries
Description: Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne.
Study: NCT06417281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Aminolevulinic Acid
Description: 3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
Study: NCT06297538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gamma transcranial alternating current stimulation (tACS)
Description: Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial alternating current stimulation (tACS)
Description: Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
Study: NCT05801601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships
Description: The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A career readiness program
Description: Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
Study: NCT05390697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
Study: NCT05605470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChulaCov19 BNA159 vaccine (50 mcg)
Description: Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer/BNT vaccine (30 mcg)
Description: Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
Description: Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
Study: NCT06173154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care system to prevent ID
Description: The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine care
Description: standard care without any specific system in place
Study: NCT04535037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Description: 3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP5-HBV-IPV-Hib
Description: 3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
Study: NCT06328699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spiritual Therapy
Description: Undergo chaplain led compassionate centered spiritual health sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive a traditional chaplain consultation and will receive care upon request